US 11,788,146 B2
Methods for therapeutics prescreening in bodily fluids
Ronen Eavri, Binyamina (IL); Annie Sabbah, Haifa (IL); Felix Badinter, Karmiel (IL); Raphael Tshuva, Nesher (IL); and Avi Schroeder, Binyamina (IL)
Assigned to BARCODE DIAGNOSTICS LTD., Nazareth (IL)
Appl. No. 16/628,210
Filed by BARCODE DIAGNOSTICS LTD., Nazareth (IL)
PCT Filed Jul. 5, 2018, PCT No. PCT/IL2018/050736
§ 371(c)(1), (2) Date Jan. 2, 2020,
PCT Pub. No. WO2019/008590, PCT Pub. Date Jan. 10, 2019.
Claims priority of provisional application 62/529,023, filed on Jul. 6, 2017.
Prior Publication US 2020/0216907 A1, Jul. 9, 2020
Int. Cl. C12Q 1/6886 (2018.01); A61K 49/00 (2006.01)
CPC C12Q 1/6886 (2013.01) [A61K 49/00 (2013.01); A61K 49/0017 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/136 (2013.01); G01N 2800/52 (2013.01)] 16 Claims
 
1. A method for predicting response of a subject afflicted with cancer to at least one therapeutic agent of a plurality of therapeutic agents, the method comprising the steps of:
(a) administering to the subject a composition comprising a plurality of types of carriers and said plurality of therapeutic agents, wherein each carrier is selected from a nanoparticle and a liposomal membrane and each type of carrier independently comprises between 0.1 and 10% of an effective therapeutic dose (ETD) of a different at least one therapeutic agent from among said plurality of therapeutic agents and one or more nucleic acid barcodes uniquely identifying said different at least one therapeutic agent from among said plurality of therapeutic agents;
(b) obtaining a fluid sample from said subject, wherein said fluid is selected from the group consisting of: blood, plasma, serum, saliva, lymph, urine, breast milk, cerebral spinal fluid and seminal fluid; and
(c) detecting, in said fluid, at least one of said unique nucleic acid barcodes of one type of carrier, wherein the presence of said unique nucleic acid barcode in said fluid indicates said subject's cancer responds to said different at least one therapeutic agent from among said plurality of therapeutic agents identified by said detected unique nucleic acid barcode;
thereby predicting response of a subject afflicted with cancer to at least one therapeutic agent of a plurality of therapeutic agents.